Structure and immunogenicity of an engineered soluble prefusion-stabilized EBV gB antigen

Journal:

Nature Communications

Published:

2026-01-03

DOI:

10.1038/s41467-025-67969-x

Affiliations:

4

Authors:

18

Go to article

Institutions	Authors	Share
Vaccine Company, United States of America (USA)	10.000000 10.000000	0.56
The University of Texas at Austin (UT Austin), United States of America (USA)	6.500000	0.36
Sanofi US, United States of America (USA)	1.000000	0.06
California Institute of Technology (Caltech), United States of America (USA)	0.500000	0.03

Interested in Medical Biotechnology?